Skip to content
Oxcia

Oxcia

  • About us
    • About us
    • Management
    • Board
    • Scientific Advisory Board
    • Collaborators
    • Partnerships
    • History
    • Careers
  • Scientific Platform
    • Scientific Platform
    • Glossary
  • Pipeline
    • Pipeline
    • OXC-101
    • OXC-201
  • Investors
    • Investors
    • Governance
    • Ownership structure
    • Financial reports
    • Presentations
    • Upcoming events
    • Investor contact
  • Investerare
    • Investerare
    • Bolagsstyrning
    • Bolagsstämmor
    • Ägarstruktur
    • Finansiella rapporter
    • Pressmeddelanden
    • Presentationer
    • Kalender
    • Investerarkontakt
  • News and Press
  • Contact
  • Search

Home › News and Press › Press releases › Page 2

News and Press releases

View all News Press releases

New publications in peer-reviewed scientific journals support the potential for OXC-101 as a novel anti-cancer therapy

June 11, 2024 · Press releases
Read article

Patent approval now also secured in the US, the largest IPF market

May 17, 2024 · Press releases
Read article

Another key milestone for OXC-201 – patent approval in China

May 3, 2024 · Press releases
Read article

Key milestone for OXC-101 – study approval in South Africa

March 21, 2024 · Press releases
Read article

Oxcia AB Publishes Year-End Report for 2023

February 22, 2024 · Press releases
Read article

Key milestone for OXC-201 – patent approval in Japan

February 21, 2024 · Press releases
Read article

Oxcia AB (publ) publishes interim report fort the third quarter 2023

November 23, 2023 · Press releases
Read article

Oxcia AB presents positive effects of OXC-201 in lung tissue from patient with Idiopatic Pulmonary Fibrosis

October 23, 2023 · Press releases
Read article

Oxcia AB (publ) publishes interim report for the second quarter 2023

August 25, 2023 · Press releases
Read article

OXC-101 as a novel therapy for AML will be presented at 18[th] Annual Congress of International Drug Discovert Science & Technology, Amsterdam 12-14 July, 2023

August 23, 2023 · Press releases
Read article

OXC-101 as a novel therapy for AML will be presented at 18[th] Annual Congress of International Drug Discovery Science & Technology, Amsterdam 12-14 July, 2023

June 30, 2023 · Press releases
Read article

Oxcia AB (publ) publishes annual report

May 16, 2023 · Press releases
Read article
« Back 1 2 3 Forward »

Contact us

Oxcia AB
Norrbackagatan 70C
113 34 Stockholm, Sweden

+46 (0)73 270 96 05

info@oxcia.com

Privacy policy

Menu

  • About us
    • About us
    • Management
    • Board
    • Scientific Advisory Board
    • Collaborators
    • Partnerships
    • History
    • Careers
  • Scientific Platform
    • Scientific Platform
    • Glossary
  • Pipeline
    • Pipeline
    • OXC-101
    • OXC-201
  • Investors
    • Investors
    • Governance
    • Ownership structure
    • Financial reports
    • Presentations
    • Upcoming events
    • Investor contact
  • Investerare
    • Investerare
    • Bolagsstyrning
    • Bolagsstämmor
    • Ägarstruktur
    • Finansiella rapporter
    • Pressmeddelanden
    • Presentationer
    • Kalender
    • Investerarkontakt
  • News and Press
  • Contact
  • Search

Social media

  • Linkedin

OXC-201

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council. Neither the European Union nor the European Innovation Council can be held responsible for them.


an EIC project aiming to bring hope to IPF patients

© Copyright Oxcia 2025 · Legal Notice · Information About Cookies

Search

More results

Generic filters